A disincentive for hospitals that have invested in expensive technology for robotic surgery may be jeopardizing prostate cancer patients who seek out the procedure, concluded a study published by Sammon et al in BJU International. The study compared complication rates in hospitals with low...
Obesity in black men substantially increased the risk of low- and high-grade prostate cancer, whereas obesity in white men moderately reduced the risk of low-grade cancer and only slightly increased the risk of high-grade cancer, according to the first large, prospective study to examine how race...
Three or more hours of walking per week can boost the vitality and health of prostate cancer survivors. Men and women who have survived colorectal cancer and are regular walkers also reported lower sensations of burning, numbness, tingling, or loss of reflexes that many often experience after...
In an analysis reported in the Journal of Clinical Oncology, Scher et al found that circulating tumor cell count and LDH level served as an individual-level surrogate for survival among patients with metastatic castration-resistant prostate cancer receiving abiraterone acetate (Zytiga) plus...
In a study reported in JAMA Oncology, Makarov et al found that hospital referral regions marked by higher rates of inappropriate imaging in patients with low-risk breast cancer also had high rates of inappropriate prostate imaging in patients with low-risk prostate cancer. Inappropriate imaging...
Numerous studies have documented racial differences in deaths from cancer among non-Hispanic whites and African Americans, but little has been known about survival outcomes for Asian Americans who have been diagnosed with cancer. In a new study published in the Journal of the National Cancer...
In a study of Swedish men with prostate cancer reported in the Journal of Clinical Oncology, O’Farrell et al found that use of gonadotropin-releasing hormone (GnRH) agonists and orchiectomy were associated with a significantly increased risk of incident cardiovascular disease. In patients...
A new study suggests that after radical prostatectomy for high-risk prostate cancer, both the age of the patient and the time survived since the operation have a significant impact on the cause of death. This means that, for young men with high-risk prostate cancer, doctors may have to reevaluate...
In an analysis from the PR-7 trial reported in the Journal of Clinical Oncology, Klotz et al found that in men with prostate cancer with biochemical failure after radiotherapy with or without surgery, a nadir serum testosterone level ≤ 0.7 nmol/L during the first year of continuous...
Current smokers, and those who have quit smoking less than 10 years previously, have twice the risk of a recurrence of prostate cancer after surgery, according to new research by Rieken et al presented at the European Association of Urology (EAU) 2015 Congress in Madrid (Abstract 508). In 2012,...
In the phase III MAINSAIL trial reported in The Lancet Oncology, Petrylak et al found that the addition of lenalidomide (Revlimid) to docetaxel-prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer was associated with significantly worse overall survival. The...
Having a family history of prostate cancer among first-degree relatives may increase a woman's risk of developing breast cancer. Researchers from multiple institutions published their findings in a study by Beebe-Dimmer et al in Cancer. The study's results indicate that clinicians should take a...
In a phase III trial (ELM-PC 5) reported in the Journal of Clinical Oncology, Fizazi et al found that the addition of the 17,20-lyase inhibitor orteronel to prednisone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel therapy resulted in an overall...
The European Randomized Study of Screening for Prostate Cancer (ERSPC) trial showed a significant 29% prostate cancer mortality reduction with prostate-specific antigen (PSA) screening but a marked negative impact on quality-adjusted life-years gained due to the effect of overdiagnosis on quality...
In a new study reported by de Leeuw et al in Clinical Cancer Research, researchers found that the novel taxane cabazitaxel (Jevtana) has properties that could make it more effective than docetaxel in some patients with advanced prostate cancer. This hypothesis is currently being tested in a phase...
In the phase III ELM-PC 4 trial reported in The Lancet Oncology, Saad et al found that the addition of the CYP 17,20 lyase inhibitor orteronel to prednisone did not improve overall survival in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. Improvement in...
In the Spanish phase III DART01/05 GICOR trial reported in Lancet Oncology, Zapatero and colleagues found that long-term androgen-deprivation therapy (ADT) increased biochemical disease-free survival and overall survival vs short-term ADT when combined with high-dose radiotherapy in men with...
Preliminary results from the phase II STAND trial have demonstrated a robust immune response with sipuleucel-T (Provenge) that continues 2 years after completing treatment in men with biochemically recurrent prostate cancer. The findings, along with data from an ongoing phase IV registry related to ...
An analysis of data on 945 patients with prostate cancer that is managed with active surveillance shows differences in outcomes depending on whether the patient was low or intermediate risk at diagnosis. Compared to patients with low-risk disease, those with intermediate-risk cancer (PSA > 10...
A case-control study of close to 180,000 men suggests that the incidence of prostate cancer is higher among men with a history of testicular cancer (12.6%) than among those without a history of testicular cancer (2.8%). Men who have had testicular cancer were also more likely to develop...
An analysis of data on roughly 87,500 men treated for prostate cancer since 2005 found a notable increase in higher-risk cases of the disease between 2011 and 2013. The retrospective analysis of patient data found the proportion of men diagnosed with intermediate- and high-risk disease increased by ...
Findings from a small prospective study suggest that androgen receptor V7 (or AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer. Treatment outcomes were largely similar for the 17 patients with...
In the final prespecified analysis of an Intergroup trial (NCIC Clinical Trials Group PR.3/Medical Research Council PR07/Intergroup T94-0110) reported in the Journal of Clinical Oncology, Mason et al found that overall survival and cancer-specific survival at 8 years were significantly greater with ...
In a study reported in the Journal of Clinical Oncology, Den et al found that a 22-biomarker genomic classifier score was predictive of a greater risk of metastasis and benefit of adjuvant vs salvage radiotherapy after radical prostatectomy for prostate cancer. Metastasis Risk The study involved...
In the Dutch phase III HYPRO trial reported in The Lancet Oncology, Aluwini et al found that hypofractionated radiotherapy was not noninferior to standard fractionated radiotherapy in acute genitourinary and gastrointestinal toxicity in men with intermediate- or high-risk prostate cancer. Efficacy...
The American Society of Clinical Oncology (ASCO) has issued an endorsement of the American Cancer Society's (ACS) Prostate Cancer Survivorship Care Guidelines. These guidelines provide recommendations to primary care physicians on best practices in follow-up care for men after prostate cancer...
Docetaxel was being widely used by patients with metastatic prostate cancer before phase III evidence that it was more effective than standard-of-care for patients with castration-resistant prostate cancer, according to an analysis of Medicare claims from before and after the trial results and...
Prostate cancer patients with detectable prostate-specific antigen (PSA) following radical prostatectomy should receive earlier, more aggressive radiotherapy, according to a study published by Wiegel et al in the International Journal of Radiation Oncology • Biology • Physics. German ARO ...
Targeted biopsy using new fusion technology that combines magnetic resonance imaging (MRI) with ultrasound is more effective than standard biopsy in detecting high-risk prostate cancer, according to a study by Siddiqui et al published in JAMA. More than 1,000 men participated in the research at the ...
In the final analysis of overall survival in the COU-AA-302 trial, reported in The Lancet Oncology by Ryan et al, the addition of abiraterone acetate (Zytiga) to prednisone significantly prolonged survival in chemotherapy-naive patients with castration-resistant prostate cancer. Abiraterone had...
According to researchers at the Johns Hopkins Kimmel Cancer Center, testosterone, which is generally thought to be a feeder of prostate cancer, has been found to suppress some advanced prostate cancers. The hormone may also reverse resistance to testosterone-blocking drugs used to treat prostate...
A new analysis opens the door to the discovery of thousands of potential new cancer biomarkers, according to a recent study by Iyer et al published in Nature Genetics. Long Noncoding RNA Researchers at the University of Michigan Comprehensive Cancer Center analyzed the global landscape of long...
As reported by Pisansky et al in the Journal of Clinical Oncology, the Radiation Therapy Oncology Group (RTOG) 9910 trial showed no benefit of extending the duration of pre–radiation therapy androgen suppression on survival or disease control among patients with localized prostate cancer....
Selenium supplementation of 140 μg/d or more after diagnosis of nonmetastatic prostate cancer may increase risk of prostate cancer mortality, according to a prospective study following 4,459 men initially diagnosed with nonmetastatic prostate cancer in the Health Professionals Follow-up Study...
In a study reported in the Journal of Clinical Oncology, Klotz et al found that 1.5% of prostate cancer patients in a Canadian active surveillance cohort died from the disease during up to 16 years of follow-up. Study Details The study involved 993 men with favorable-risk prostate cancer who were ...
Adding radiation treatment to androgen-deprivation therapy saves more lives among older men with locally advanced prostate therapy than androgen-deprivation therapy alone, according to a new study reported by Bekelman et al in the Journal of Clinical Oncology. The researchers found that...
In a study reported in the Journal of Clinical Oncology, Wei et al found that use of urinary prostate cancer antigen 3 (PCA3) measurement could improve avoidance of repeat prostate biopsy and detection of prostate cancer in biopsy-naive patients. This National Cancer Institute study involved...
Men with localized prostate cancer who walked or cycled for 20 minutes or more a day had a 30% decreased overall mortality and a 39% decreased prostate cancer–specific mortality compared with men who spent less time engaging in those activities, a large Swedish study has found. The study...
Results from the ARMOR2 of the anticancer drug galeterone shows that it is successful in lowering prostate-specific antigen (PSA) levels in men with a variant form castration-resistant prostate cancer. The findings, presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer...
A recent analysis of a large clinical database indicated that postdiagnosis aspirin use was associated with a 57% reduction in prostate cancer–specific mortality among men with nonmetastatic prostate cancer. In a study in a prospective cohort reported in the Journal of Clinical Oncology,...
In a recent study, use of solifenacin was associated with a statistically significant improvement in continence in patients who underwent robotic-assisted radical prostatectomy, although no statistically significant difference in the time to return to continence. The results of this study,...
In a phase II study reported in the Journal of Clinical Oncology, Taplin et al found that the addition of neoadjuvant abiraterone acetate (Zytiga) to the luteinizing hormone–releasing hormone (LHRH) agonist leuprolide acetate resulted in greater suppression of intraprostatic androgens in...
The American Society of Clinical Oncology (ASCO) today issued an endorsement of the American Urological Association (AUA)/American Society for Radiation Oncology (ASTRO) guideline on the use of adjuvant and salvage radiotherapy after prostatectomy, which was based on a systematic review of medical...
The phase III ALSYMPCA trial showed that radium-223 (Xofigo) increased overall survival vs placebo patients with castration-resistant prostate cancer and symptomatic bone metastases. In a prespecified subgroup analysis reported in The Lancet Oncology, Hoskin et al found that overall survival...
While early treatment of prostate cancer recurrence after a radical prostatectomy based on detectable or rising prostate-specific antigen (PSA) levels may reduce the risk of disease metastasis, even without salvage treatment, many patients will die of other causes before metastatic disease...
Prostate cancer survivors with higher levels of total cholesterol and triglycerides had an increased risk for disease recurrence, according to a study by Allott et al. The study findings, coupled with evidence that statin use is associated with reduced recurrence risk, suggest that lipid levels...
In an analysis of outcomes in patients with node-positive prostate cancer reported in the Journal of Clinical Oncology, Abdollah et al found that adjuvant radiotherapy is associated with a survival benefit in patients with low-volume nodal disease in the setting of intermediate- to high-grade...
Abiraterone acetate (Zytiga) is approved for use in combination with prednisone in the treatment of metastatic castration-resistant prostate cancer. As reported by Sternberg et al in The Lancet Oncology, results of an open-label, early-access protocol trial initiated prior to approval indicated no...
The androgen receptor isoform encoded by splice variant 7 is constitutively active as a transcription factor, despite lacking the ligand-binding domain that is the target of enzalutamide (Xtandi) and abiraterone (Zytiga). In a study reported in The New England Journal of Medicine, Antonarakis et al ...
Researchers at The University of Texas MD Anderson Cancer Center have identified a biomarker adjacent to the KLK3 gene that can predict which prostate cancer patients with a Gleason score of 7 will have a more aggressive form of cancer. The findings by He et al, published in Clinical Cancer...